Profil
Cory L.
Grand worked as a Director of Assay Development at Montigen Pharmaceuticals, Inc. and as a Project Manager of Drug Development at SuperGen, Inc. He earned a doctorate degree from the University of Arizona.
Ehemalige bekannte Positionen von Cory L. Grand
| Unternehmen | Position | Ende |
|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Corporate Officer/Principal | 13.09.2011 |
Montigen Pharmaceuticals, Inc.
 Montigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Montigen Pharmaceuticals, Inc. developed pharmaceutical products used for the treatment of cancer. Its products addressed oncology drug market with demonstrated preclinical activity in various solid tumor types, including pancreatic, colorectal, breast, prostate, and ovarian cancers. The company was founded in 2003 and was headquartered in Salt Lake City, UT. | Corporate Officer/Principal | - |
Ausbildung von Cory L. Grand
| University of Arizona | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Montigen Pharmaceuticals, Inc.
Montigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Montigen Pharmaceuticals, Inc. developed pharmaceutical products used for the treatment of cancer. Its products addressed oncology drug market with demonstrated preclinical activity in various solid tumor types, including pancreatic, colorectal, breast, prostate, and ovarian cancers. The company was founded in 2003 and was headquartered in Salt Lake City, UT. | Health Technology |
